{"organizations": [], "uuid": "8041338bf9b72c6b14cc1d778c821992a678054b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-vbi-vaccines-posts-positive-dsmb-r/brief-vbi-vaccines-posts-positive-dsmb-review-of-recurrent-glioblastoma-study-idUSFWN1RU0TJ", "country": "US", "domain_rank": 408, "title": "BRIEF-VBI Vaccines Posts Positive DSMB Review Of Recurrent Glioblastoma Study", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-17T15:13:00.000+03:00", "replies_count": 0, "uuid": "8041338bf9b72c6b14cc1d778c821992a678054b"}, "author": "", "url": "https://www.reuters.com/article/brief-vbi-vaccines-posts-positive-dsmb-r/brief-vbi-vaccines-posts-positive-dsmb-review-of-recurrent-glioblastoma-study-idUSFWN1RU0TJ", "ord_in_thread": 0, "title": "BRIEF-VBI Vaccines Posts Positive DSMB Review Of Recurrent Glioblastoma Study", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-vbi vaccines posts positive dsmb review of recurrent glioblastoma", "sentiment": "negative"}, {"name": "glioblastoma", "sentiment": "none"}, {"name": "vbi vaccines inc", "sentiment": "none"}, {"name": "vbi vaccines inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 13 PM / Updated 24 minutes ago BRIEF-VBI Vaccines Posts Positive DSMB Review Of Recurrent Glioblastoma Study Reuters Staff 1 Min Read \nApril 17 (Reuters) - VBI Vaccines Inc: \n* VBI VACCINES ANNOUNCES POSITIVE DSMB REVIEW IN PHASE 1/2A STUDY OF VBI-1901 IN RECURRENT GLIOBLASTOMA (GBM) PATIENTS \n* VBI VACCINES INC - INDEPENDENT DATA AND SAFETY MONITORING BOARD UNANIMOUSLY RECOMMENDS CONTINUATION OF STUDY WITHOUT MODIFICATION \n* VBI VACCINES INC - INITIATED ENROLLMENT IN INTERMEDIATE-DOSE ARM OF DOSE-ESCALATION PHASE OF STUDY Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-17T15:13:00.000+03:00", "crawled": "2018-04-17T15:31:22.009+03:00", "highlightTitle": ""}